CreditAccess Grameen Limited
Financial trend (100/100) does the heavy lifting; valuation (20/100) is the drag.
Fair valueOvervaluedCreditAccess Grameen Limited earns a Hold from StocksWizard, with a blended score of 45/100. At ₹1,592.8 it trades above our blended DCF and relative-multiples fair value of ₹796.4, about 50% downside to that estimate — we read it as overvalued by 50%. On 30.2x trailing earnings it sits pricier than the Financial Services median of about 24.3x. It's trading right at its 52-week high of ₹1,614. Financial health scores 76/100, with a Piotroski F-score of 3/9. The average analyst target of ₹1,708.2 implies about 7% upside across 15 analysts. It clears 6 of 12 investability checks, with durability 64, valuation 39 and momentum 77 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹637.12.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-1.31% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 3/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 10.5%
- Fail: Low debt (D/E < 0.5): 3.03x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 138%
- Pass: Earnings growing: 616%
- Pass: Net margin ≥ 10%: 32.0%
- Pass: Current ratio > 1.5: 2.29
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- No data: Altman Z in safe zone
- Fail: Piotroski ≥ 7: 3/9
Quarterly results
Annual financials
Shareholding
- Promoter66.2%
- Institutions17.5%
- Public & other16.2%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Healthy profit margin (32.0%).
- Trading near its 52-week high.
Opportunities
- Earnings growing (616% YoY).
- Revenue growing (138% YoY).
Bear case
Weaknesses
- High debt relative to equity.
- Weak Piotroski score (3/9).
Threats
- Trades ~50% above our estimated fair value.
About CreditAccess Grameen Limited
CreditAccess Grameen Limited, a non-banking financial company, provides micro finance services for women from poor and low-income households in India. The company offers microcredit loans for income generation, home improvement, emergency, family welfare, and Grameen Unnati, as well as Grameen Suraksha, Grameen Sanchay, life insurance, and national pension schemes. It also provides retail finance loans, such as Grameen Vikas, Unnati loan, Grameen two-wheeler, Grameen Vishesh
CreditAccess Grameen Limited — frequently asked questions
Is CreditAccess Grameen Limited a buy, hold or sell?
StocksWizard currently rates CreditAccess Grameen Limited (CREDITACC) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is CreditAccess Grameen Limited's fair value?
Our blended DCF and relative-valuation model estimates CreditAccess Grameen Limited's fair value at about ₹796.4, versus a current price of ₹1,592.8 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is CreditAccess Grameen Limited financially healthy?
CreditAccess Grameen Limited scores 76/100 on our financial-health model, with a Piotroski F-score of 3/9.
How has CreditAccess Grameen Limited's share price performed?
CreditAccess Grameen Limited is up 5% over three months, and last traded at ₹1,592.8. Past performance doesn't predict future returns.
More in Financial Services
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.